Leerink Partners reiterates outperform rating for Kura Oncology stock

Kura Oncology's NDA for ziftomenib, a treatment for relapsed or refractory NPM1-mutated AML, has been accepted by the FDA and granted priority review with a PDUFA date of November 30, 2025; this follows positive Phase 2 KOMET-001 trial results showing a 23% complete remission rate and aligns with Leerink Partners' Outperform rating and $23 price target. Kura Oncology's Q1 2025 revenue increased to $14.1 million, but EPS missed estimates, and the company is preparing to release updated Phase Ib data at the EHA Congress in June 2025, reinforcing ziftomenib's potential in AML treatment.

Analysis

Kura Oncology has achieved a significant regulatory milestone with the U.S. FDA's acceptance and priority review designation for its New Drug Application (NDA) for ziftomenib in relapsed or refractory NPM1-mutated acute myeloid leukemia (AML), setting a PDUFA target action date of November 30, 2025. This advancement is substantiated by the KOMET-001 Phase 2 trial data, presented fully at ASCO, which demonstrated a 23% complete remission rate among 92 patients and a favorable safety profile, reinforcing ziftomenib's positive benefit-risk assessment. Analyst sentiment is strongly positive, with Leerink Partners reiterating an Outperform rating and a $23.00 price target—a significant premium to the current $6.30 share price—and InvestingPro data indicating a strong Buy consensus with targets ranging from $8 to $40, alongside a suggestion that the stock is undervalued. Kura Oncology's financial health appears solid, with a current ratio of 8.07, a net cash position, and sufficient cash reserves projected to fund operations into 2027; this is despite a Q1 2025 earnings per share of -$0.66, which missed the -$0.62 forecast, even as revenue grew to $14.1 million from zero year-over-year. An upcoming catalyst is the presentation of updated Phase Ib KOMET-007 data, combining ziftomenib with intensive chemotherapy for first-line AML, at the European Hematology Association (EHA) Congress on June 12, 2025, further elucidating the drug's potential.

Key Decisions for Investors

• Investors should closely monitor the upcoming Phase Ib KOMET-007 data presentation at the EHA Congress on June 12, 2025, as a near-term catalyst that could further validate ziftomenib's potential in a broader AML patient population.
• The PDUFA date of November 30, 2025, for ziftomenib represents a critical regulatory milestone; a positive FDA decision could significantly de-risk the asset and positively impact Kura Oncology's valuation, while a negative outcome would pose a substantial setback.
• While the company's financial position is robust with a cash runway into 2027 and emerging revenue, the Q1 EPS miss warrants attention in subsequent quarterly reports to ensure operational spending aligns with strategic development goals and timelines.